Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Idorsia grosses $508.9mm in combined equity and debt offerings

Executive Summary

Idorsia Pharmaceuticals Ltd. grossed CHF505mm ($508.9mm) in combined equity and debt offerings. The company placed 11.9mm new shares at CHF25.62 ($25.81) per share for gross proceeds of CHF305mm ($307.4mm) and simultaneously secured CHF200mm ($201.5mm) in senior convertible redeemable bonds.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • FOPO
    • Venture Financing

Related Companies